RxDoctor Payments Data

Keith Stolte, MD

Ophthalmology · Spring Hill, FLNPI 1144286428

Payments from drug & device makers

$1,376in general payments, 2019–2025

Across 71 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$507
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$153
  • Kala Pharmaceuticals, Inc.$146
  • Alcon$142
  • AbbVie$135
  • Mallinckrodt Hospital Products Inc.$67
  • plus $227 from 9 others

What the payments were for

  • Food & beverage$1,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,376 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$145,522
Medicare patients
285
Services billed
1,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VabysmoFaricimab-Svoa14$48,555
LumiganBimatoprost55$24,239
RhopressaNetarsudil Mesylate23$13,608
Difluprednate107$12,925
RocklatanNetarsudil Mesylat/Latanoprost27$11,219
Alphagan PBrimonidine Tartrate19$10,328
RestasisCyclosporine14$9,364
CombiganBrimonidine Tartrate/Timolol14$5,518
Prednisolone Acetate149$5,112
MoxifloxacinMoxifloxacin Hcl249$5,031
Latanoprost350$4,293
Travoprost33$3,291
Loteprednol Etabonate14$2,018
Timolol Maleate129$1,233
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat62$1,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$135$49,448102 claims
Genentech USA, Inc.Vabysmo$18$48,55514 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$153$2,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →